|Bid||4.91 x 2200|
|Ask||5.00 x 3100|
|Day's Range||4.6200 - 5.0300|
|52 Week Range||2.6400 - 9.2900|
|Beta (3Y Monthly)||-0.14|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 13, 2019 - Mar 18, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||9.50|
As recession fears emerge amid slowing global growth, signals are emerging of a possible resurgence in gold, precious metals, and the mining industry as a whole. The public mining sector has been stagnant (for investors) for most of the 10-year U.S. economic boom, but that could be changing. Gold has finally found a bid, and M&A among major industry players is booming as they scoop up under-appreciated assets.
Amyris, Inc. (AMRS), and IDRI (Infectious Disease Research Institute), are pleased to announce IDRI’s receipt of a $4.4 million, five-year grant from the National Institute of Allergy and Infectious Diseases (part of the U.S. National Institutes of Health) to discover sustainable alternatives to shark squalene to use as vaccine adjuvants (grant number: R01AI135673). IDRI has selected Amyris and the University of Nottingham, (UK) as partners because of their record of success in engineering pure molecules from sustainable sources at low cost.
Amyris, Inc. (AMRS), a leader in the development and production of sustainable ingredients for the Health & Wellness, Clean Beauty and Flavors & Fragrances markets, today announced the appointment of Oreste Fieschi as President of Sweeteners & Ingredients, to lead the commercial growth of its sweetener business and the implementation of its strategy to build capability across the entire ingredients portfolio. Oreste has a successful track record in commercial leadership roles in the food and beverage and natural ingredients sectors, along with deep expertise in global markets. This new position is driven by growth across Amyris’s businesses and within the expanding market for the company’s new, sugarcane-derived zero calorie sweetener.
CORAL GABLES, FL / ACCESSWIRE / February 8, 2019 / The marijuana stock market, as many have come to recognize, has existed for a short period of time relative to other more established markets. Due to this fact, there have been quite a bit of volatility surrounding companies in the cannabis industry. As we continue to move through the month of February, the hope is that the cannabis industry will recognize even more gains in the future.
Investors can now consider renewable products company Amyris (NASDAQ:AMRS) as a "marijuana stock." The Emeryville, California-based firm signed a deal to license cannabinoid products. This sent AMRS stock surging much higher in Tuesday trading.Now, investors must decide if and how to trade Amyris stock. Given the renewed popularity of marijuana stocks, the stock will likely remain a momentum stock for the foreseeable future. New Deal Changes the Perception of AMRS StockAMRS stock rose by more than 73% on Tuesday upon announcing its entrance in the cannabinoid market. The company did not reveal the name of its partner in this agreement; however, we know the value of the deal will come to $255 million. Some of this could come in the form of royalty payments as Amyris works to bring sustainably sourced CBD to the beverage and skin care markets. The final agreement should happen by the end of March. Products from this deal should appear on shelves 18 to 24 months after final approval.InvestorPlace - Stock Market News, Stock Advice & Trading TipsBefore this agreement, Amyris survived as a little-known industrial biotech company that launched its IPO in 2010. Since peaking in 2011, the stock has lost about 99% of its value. Now, thanks to cannabis, it could be on its way to a long-awaited comeback. The Deal Will Bolster Robust Revenue GrowthWhile the association with weed will likely boost AMRS stock, its financials have shown improvement for some time. In the middle of the decade, stagnant revenue and massive losses seem to define AMRS. * 7 Recession-Proof Stocks to Buy as the Boom Ends However, the company more than doubled revenues in 2016 and again in 2017. Although this growth has slowed, analysts had predicted revenue increases would remain well into the double digits before this announcement. Losses have also narrowed in recent years. With cannabis-related sales coming in, both revenue and earnings should improve dramatically.Also, even after its massive upward surge, AMRS trades at just over two times sales. This compares well to cannabis industry giants such as Canopy Growth (NYSE:CGC) and Tilray (NASDAQ:TLRY), both of which maintain triple-digit price-to-sales ratios.Furthermore, Canopy's market cap of nearly $16 billion is more than 40 times the size of Amyris's $390 million market cap. Yet with 2018 revenues of only C$255 million ($193.4 million), Canopy will only bring in about 20% more in revenue than the $161.8 million analysts expect from Amyris. While I do not think AMRS will catch up to Canopy's market cap, I think this deal will help close much of that gap. AMRS Could Benefit From an American Cannabis BoomMoreover, marijuana stock investors remember the Canadian cannabis boom that cooled off following full legalization. Now, with hemp achieving legal status in the U.S., a comparable American cannabis boom looks to have just begun. Canopy, who will begin producing hemp in New York, again trades at levels not seen since legal status became official in Canada. * 10 F-Rated Stocks That Could Break Your Portfolio If such a boom has in fact started in the U.S., this should bode well for AMRS stock regardless of fundamentals. Given the 73% surge in one day, the stock will more likely pull back for now. However, over time, the boom in cannabis stocks should take it higher. This separation from fundamentals will turn off some buyers. However, for those comfortable trading mostly on momentum, I see the potential for profit in Amyris stock. Final Thoughts on Amyris StockThe move into the cannabis sector will boost Amyris stock in the near term regardless of earnings. Amyris has spent years as a little-known biotech company whose stock had gained little traction in recent years. However, a move into the marijuana sector sent AMRS more than 70% higher in just one day.This occurs as a U.S. cannabis boom has likely ignited thanks to hemp's new legal status. Despite losses, AMRS stock looks cheap in comparison to marijuana giants such as Canopy Growth. If nothing else, the momentum should take the company's price-to-sales ratio much higher.Like other marijuana stocks, AMRS should grow well beyond its fundamentals. This will mean any movement or purchase decisions will drive on momentum shifts. This goes beyond the comfort level of some investors. However, for those willing to take that risk, AMRS appears poised to bring higher returns to those with a high tolerance for risk.As of this writing, Will Healy did not hold a position in any of the aforementioned securities. You can follow Will on Twitter at @HealyWriting. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Stocks That Won Super Bowl Sunday * 7 High-Yield ETFs for Brave Investors * 10 F-Rated Stocks That Could Break Your Portfolio Compare Brokers The post Amyris Stock Can Run Much Higher Than You Think appeared first on InvestorPlace.
Shares of bioscience firm Amyris (AMRS) skyrocketed more than 70% on Tuesday after the company announced a collaboration deal focused on developing, licensing, and commercializing cannabinoid products.
Although society has progressed much further in terms of recognizing the potential benefits of cannabis, there are still individuals who have yet to come to terms with the fact that more people are supportive of legalization. As a result of the recent passing of laws like the US Farm Bill, as well as Canada's country-wide legalization, individuals who would otherwise scoff at the cannabis industry, have now been brought into the fold due to the excitement surrounding the industry. Nabis Holdings (INNPF) (NAB), Amyris Inc (AMRS), InMed Pharmaceuticals Inc (IMLFF) (IN.TO), and Pyxus International Inc (PYX) are four cannabis companies working towards improving the quality of life for their consumers.
(Bloomberg) -- A $255 million deal to convert sugar into cannabis-chemicals is opening the door to an era of pot without plants.
There's a new bit of Amyris news that has AMRS stock flying high on Tuesday. Source: Shutterstock Amyris (NASDAQ:AMRS) has announced that it has signed a deal for partnership development, licensing and commercialization of cannabinoid products. The company isn't currently revealing the other party in the deal. What the Amyris news does reveal is that this partnership is worth $255 million. This includes one upfront payment to the company, as well as several others over the next 12 months to 36 months. InvestorPlace - Stock Market News, Stock Advice & Trading Tips AMRS is also eligible to receive royalty payments in connection to the cannabinoid products. The company says that it is expecting this to result in significant royalty payments due to the size of the cannabinoid market. "We are pleased to have been recognized by a well-capitalized partner as the company best suited to leverage fermentation-based technology in the production of the best quality and lowest cost and sustainably-produced cannabinoids," John Melo, President and CEO of AMyris, said in a statement. "We share the mission of our partners to become the leader in sustainably-sourced CBD products in the near term as we focus on enabling the global beverage and skin care markets, including our own brands, to support the health and wellness of people and our planet." * 7 Stocks That Won Super Bowl Sunday Amyris says that it and its partner are expecting to sign off on a final agreement by the end of March. It will begin development right after this and expects to have products ready for the market in the following 18 months to 24 months. AMRS stock was up 41% as of noon Tuesday. ### More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 F-Rated Stocks That Could Break Your Portfolio * 5 Fintech Stocks to Buy As This Mega Trend Gains Steam * 10 Cold Weather Stocks to Heat Up Your Returns As of this writing, William White did not hold a position in any of the aforementioned securities. Compare Brokers The post Amyris News: AMRS Stock Explodes on Cannabinoid Deal appeared first on InvestorPlace.
Amyris, Inc. (AMRS), a leader in the development and production of sustainable ingredients for the Health & Wellness, Clean Beauty and Flavors & Fragrances markets, today announced that it has signed a binding term sheet for a planned cannabinoid development, licensing and commercialization partnership valued at up to $255 million (not including significant royalties once the products are commercialized) with a confidential partner. Amyris has a successful track record of leveraging its unique technology platform to scale No Compromise™ sustainable products and successfully bring them to commercialization. In addition to lab-based milestone payments, this agreement also provides for significant milestone payments for commercially scaling each product.
LOS ANGELES, CA / ACCESSWIRE / February 1, 2019 / LD Micro is pleased to announce that the LD Micro Index is being reconstituted as of February 1, 2019. Again. We have always held the belief that our industry ...
The synthetic-biology pioneer has wooed investors with grandiose plans for 2019 and beyond. A look at past promises suggests failure is a more likely outcome.
Amyris, Inc. (AMRS), a leader in the development and production of sustainable ingredients for the Health & Wellness, Clean Beauty and Flavors & Fragrances markets, today announced that it has signed a long-term agreement with Xinfu of China for a significant initial payment and a long-term minimum annual share of an existing nutritional product royalty arrangement. This agreement enables Amyris to monetize a portion of the long-term royalty opportunity for this product upfront to better manage volatility in a high-margin revenue stream while maintaining access to future upside in the royalty payment structure. “We are very pleased with our relationship with Xinfu, which is an extension of existing strong relationships we have built within China over the last year,” said John Melo, Amyris President & CEO.
At Insider Monkey we track the activity of some of the best-performing hedge funds like Appaloosa Management, Baupost, and Third Point because we determined that some of the stocks that they are collectively bullish on can help us generate returns above the broader indices. Out of thousands of stocks that hedge funds invest in, small-caps […]
For more than thirty years, Philip Hempleman’s Ardsley Partners has been focusing on generating attractive returns to clients, by picking the best stocks and managing portfolios designed to seek out opportunity. This Stamford, Connecticut-based, long-short equity management firm, is launched back in March 1987 by Philip Hempelman, its current Managing Partner, Chief Investment Officer, and […]
Amyris, Inc. (AMRS), a leader in the development and production of sustainable ingredients for the Health & Wellness, Clean Beauty and Flavors & Fragrances markets, announced today that it has received a successful GRAS notification from the US Food and Drug Administration (FDA) for its zero calorie sweetener. With this notification, the FDA has accepted the unanimous conclusion of a panel of food-safety experts, we announced on August 30, 2018, that Amyris’s zero calorie sweetener made from sugarcane is safe for use as a sweetener. The sweetener has the highest level of purity available today, the best taste of any alternative sweetener, and is made from a sustainable production process using fermentation.
Amyris, Inc. (AMRS) (the “Company”), a leader in the development and production of sustainable ingredients for the Health & Wellness, Clean Beauty and Flavors & Fragrances markets, today announced that it has successfully closed on the previously-announced sale of $60 million of unsecured convertible senior notes (the "Notes"), in a private placement with two “accredited investors” (as defined in Rule 501 of Regulation D promulgated under the Securities Act of 1933). “We are very pleased with the support of our investors in addressing and simplifying our debt while we continue to deliver significant product sales growth across our business and pursue a truly exciting opportunity for us to disrupt the sweetener market with a healthier alternative,” said John Melo, Amyris President and CEO.
Gilead's CEO search, Amyris' cannabis consideration and Principia's opportunity in this week's Health Care Digest.
EMERYVILLE, Calif. and LEÓN, Spain, Dec. 10, 2018 (GLOBE NEWSWIRE) -- Amyris, Inc. (AMRS), a leader in the development and production of pure, sustainable, fermentation-derived ingredients for Health & Wellness, Clean Beauty and Flavors & Fragrances markets, today announced that it has executed an expanded agreement for its existing production contract with ADL Bionatur Solutions (MAB:ADL), through its fermentation division ADL Biopharma. ADL Bionatur, a European leader in research and development of health products, services and industrial fermentation production, provides cost effective, contract manufacturing capabilities.
Amyris, Inc. (AMRS), a leader in the development and production of sustainable ingredients for the Health & Wellness, Clean Beauty and Flavors & Fragrances markets, announced the accelerated commercialization of its new zero calorie, sugarcane-derived sweetener in 2019 in partnership with several food and beverage industry leaders. Amyris and its partners are ushering in the next wave in better-for-you, better-for-the planet sweeteners. While many other sweeteners on the market today are made with impurities that may result in a bitter aftertaste, Amyris’s sweetener is made from sugarcane using a proprietary process of fermentation to create the product at scale, yielding a sweetener with 95 percent purity – far higher than competitors.
The Bay area company Amyris unveils a zero calorie naturally sourced sweetener in an attempt to carve out health issues for consumers. Yahoo Finance’s Alexis Christoforous speaks to Amyris CEO John Melo.